Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Salarius Pharmaceuticals stock

Own Salarius Pharmaceuticals stock in just a few minutes.

Salarius Pharmaceuticals, Inc is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Salarius Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Salarius Pharmaceuticals share price

Use our graph to track the performance of SLRX stocks over time.

Salarius Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$0.63 - $3.50
50-day moving average $1.40
200-day moving average $1.21
Wall St. target price$4.43
PE ratio 1.803
Dividend yield N/A (0%)
Earnings per share (TTM) $-176.44

Buy Salarius Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Salarius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Salarius Pharmaceuticals under- or over-valued?

Valuing Salarius Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Salarius Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Salarius Pharmaceuticals's P/E ratio

Salarius Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Salarius Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Salarius Pharmaceuticals financials

Revenue TTM $5.2 million
Gross profit TTM $-1,680,552
Return on assets TTM -25.07%
Return on equity TTM -44.91%
Profit margin -140.49%
Book value $0.93
Market capitalisation $53.2 million

TTM: trailing 12 months

Shorting Salarius Pharmaceuticals shares

There are currently 1.6 million Salarius Pharmaceuticals shares held short by investors – that's known as Salarius Pharmaceuticals's "short interest". This figure is 41.4% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Salarius Pharmaceuticals shares can be evaluated.

Salarius Pharmaceuticals's "short interest ratio" (SIR)

Salarius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Salarius Pharmaceuticals shares currently shorted divided by the average quantity of Salarius Pharmaceuticals shares traded daily (recently around 1.5 million). Salarius Pharmaceuticals's SIR currently stands at 1.03. In other words for every 100,000 Salarius Pharmaceuticals shares traded daily on the market, roughly 1030 shares are currently held short.

However Salarius Pharmaceuticals's short interest can also be evaluated against the total number of Salarius Pharmaceuticals shares, or, against the total number of tradable Salarius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Salarius Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Salarius Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0355% of the tradable shares (for every 100,000 tradable Salarius Pharmaceuticals shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Salarius Pharmaceuticals.

Find out more about how you can short Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals share dividends

We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.

Have Salarius Pharmaceuticals's shares ever split?

Salarius Pharmaceuticals's shares were split on a 1:25 basis on 21 July 2019. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.

Salarius Pharmaceuticals overview

Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site